Skip to main content
  • INVEST IN OUR FUTURE
  • INVEST IN OUR FUTURE
  • INVEST IN OUR FUTURE

A FOCUSED INVESTMENT STRATEGY

Xerys is a portfolio management company specializing in private equity, with an approach that places the entrepreneur’s vision at the heart of its investment philosophy. The aim is to support the managers of Xerys portfolio companies at every stage of their growth, from venture capital to maturity.


JACQUES SIMONNET

JACQUES SIMONNET

Chairman of the Supervisory Board and Founder

OLIVIER OSSIPOFF

OLIVIER OSSIPOFF

Chairman & CEO

OUR PHILOSOPHY

The Xerys approach

“Xerys was created in response to the need to reconcile two major challenges for business growth. On the one hand, entrepreneurs wishing to achieve their growth ambitions need appropriate financial support, as well as strategic and operational guidance. On the other hand, investors are looking for transparency and control over their investments….


OUR STRATEGY

AN ORIGINAL APPROACH TO PRIVATE EQUITY

100%

INDEPENDENT


15-90M€

INVESTMENT
TICKET


6

COMPANIES
IN PORTFOLIO

2014

Approval from the
Financial Markets

Strong expertise

Xerys Invest’s governance is structured around a supervisory board and a management board with complementary experience.

Strong involvement

The management team and experts are involved in the monitoring of investments.

Convergent interests

The management team is systematically interested in investment performance.

From the outset, Xerys establishes a close, constructive and proactive relationship with the managers of its investments, to support and advise them in their strategic decision-making, trade-offs and value creation. With this original approach, Xerys establishes a relationship of trust with managers and investors, fostering shared value creation over the medium term. Through our various investment vehicles, we enable our investors to track the performance of selected companies.

2  INVESTMENT SECTORS

Life Science

Sustainable
development

NEWS

Biolog-id

Biolog-id is awarded a contract with IPST funded by the European Commission for the use of Biolog-id Transfusion solution.

IPST, a recognized healthcare institution located in Portugal, decides to adopt the Biolog-id Transfusion solution following a tender awarded to ...
Alzprotect

ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT

Alzprotect, a biopharmaceutical company based in Lille, is currently testing an innovative drugagainst a neurodegenerative disease closely related to Alzheimer's ...
Advanced Biodesign

ADVANCED BIODESIGN, WINNER OF THE FRANCE 2030 PLAN’S CALL FOR “i-DEMO” PROJECTS TO FINANCE ITS “ODYSSEY” CLINICAL TRIAL WITH UP TO €3M

Advanced BioDesign's winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia ...

OUR PARTICIPATIONS

XERYS FRANCE

73 boulevard haussmann

75008 Paris - France

+33 (0)1 82 52 12 25

FOLLOW-US: